Brugada syndrome risk factors

Jump to navigation Jump to search

Brugada syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Brugada syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Examples of Type I Brugada Syndrome

Chest X Ray

Echocardiography or Ultrasound

Electrophysiologic Studies

Genetic Testing

Treatment

Treatment

Drugs to Avoid

Drugs to Preferably Avoid

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Brugada syndrome risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Brugada syndrome risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Brugada syndrome risk factors

CDC on Brugada syndrome risk factors

Brugada syndrome risk factors in the news

Blogs on Brugada syndrome risk factors

Directions to Hospitals Treating Brugada syndrome

Risk calculators and risk factors for Brugada syndrome risk factors

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Risk Factors: Agents and Scenarios that Provoke the Brugada Syndrome Pattern

The findings of Brugada syndrome are often concealed, but can be unmasked or modulated by a number of drugs and pathophysiological states including:

Risk Statification

  • Patients with syncope and an abnormal Type 1 ECG are at higher risk
  • Asymptomatic patients at risk can be identified
    • Presence of spontaneous Type 1 ST-segment elevation
    • Characteristics of the S wave
    • Presence of late potentials
    • Inducibility of VT/VF using PES is controversial as a risk factor.

References

Template:WH Template:WS